Tesamorelin Acetate

CHEMBL2111290 Phase 4 Одобрено Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Tesamorelin acetate is the acetate salt form of tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy. See tesamorelin for complete pharmacological details. This salt formulation is used in approved injectable preparations for subcutaneous administration.

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Tesamorelin acetate is the acetate salt form of tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy. See tesamorelin for complete pharmacological details. This salt formulation is used in approved injectable preparations for subcutaneous administration.

Yes, Tesamorelin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111290. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.